Geode Capital Management LLC grew its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 2.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,152,628 shares of the medical device company's stock after acquiring an additional 32,676 shares during the quarter. Geode Capital Management LLC owned about 2.36% of AtriCure worth $32,326,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors also recently modified their holdings of the company. Canada Pension Plan Investment Board lifted its stake in shares of AtriCure by 187.7% in the second quarter. Canada Pension Plan Investment Board now owns 110,669 shares of the medical device company's stock valued at $2,520,000 after buying an additional 72,200 shares in the last quarter. State Street Corp grew its holdings in AtriCure by 4.9% during the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock worth $37,710,000 after buying an additional 63,002 shares in the last quarter. Atom Investors LP purchased a new stake in AtriCure in the 3rd quarter valued at $1,741,000. Renaissance Technologies LLC lifted its stake in AtriCure by 12.8% during the 2nd quarter. Renaissance Technologies LLC now owns 171,700 shares of the medical device company's stock valued at $3,910,000 after acquiring an additional 19,500 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in AtriCure during the 3rd quarter worth $488,000. 99.11% of the stock is currently owned by institutional investors.
AtriCure Price Performance
Shares of NASDAQ ATRC traded up $0.25 during trading hours on Thursday, reaching $30.75. 264,989 shares of the stock traded hands, compared to its average volume of 689,851. The company's 50-day simple moving average is $33.41 and its two-hundred day simple moving average is $27.68. The company has a market capitalization of $1.50 billion, a P/E ratio of -37.05 and a beta of 1.40. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $39.04. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13.
AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. The company had revenue of $115.91 million during the quarter, compared to analysts' expectations of $112.23 million. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The firm's revenue was up 17.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.20) EPS. Equities research analysts forecast that AtriCure, Inc. will post -0.72 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on the stock. Canaccord Genuity Group raised their price target on shares of AtriCure from $53.00 to $61.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Oppenheimer boosted their target price on AtriCure from $32.00 to $36.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. UBS Group increased their price target on AtriCure from $35.00 to $40.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. StockNews.com raised shares of AtriCure from a "sell" rating to a "hold" rating in a report on Saturday, September 14th. Finally, JPMorgan Chase & Co. reaffirmed an "overweight" rating and set a $40.00 target price on shares of AtriCure in a report on Tuesday, December 17th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $42.00.
Check Out Our Latest Analysis on ATRC
About AtriCure
(
Free Report)
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
See Also
Before you consider AtriCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AtriCure wasn't on the list.
While AtriCure currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
